Riehl melanosis - Melanosis Riehlhttps://en.wikipedia.org/wiki/Riehl_melanosis
Is cineál dermatitis teagmhála é Melanosis Riehl (Riehl melanosis) , ag tosú le pruritus, éiritime, agus lí a leathnaíonn de réir a chéile, a thagann chun bheith ina stad, tar éis dó achar áirithe a bhaint amach. D'fhéadfadh nochtadh gréine tar éis úsáid a bhaint as roinnt cumhrán nó uachtair an chúis leis an ngalar.

☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
      References Riehl Melanosis 32491369 
      NIH
      Riehl melanosis a dtugtar go minic mar dheirmitíteas teagmhála pigmented. Is cineál riocht craiceann é de bharr ailléirgí, a spreagann cumhráin agus substaintí eile a fhaightear i dtáirgí cosmaideacha de ghnáth. In ainneoin a bheith rangaithe mar chineál dheirmitíteas, léiríonn Riehl melanosis athruithe pigmentation sa chraiceann, gan ach comharthaí beaga greannú. Tá sé níos coitianta i ndaoine a bhfuil tones craiceann níos dorcha acu. Tá iniúchadh déanta ag taighde le déanaí ar éifeachtacht na cóireála léasair mid-fluence QSNY 1064-nm chun aghaidh a thabhairt ar an lí dhomhain a bhaineann le Riehl melanosis. Chuir staidéar eile teiripí éagsúla le chéile, lena n-áirítear léasair low-fluence 1064-nm Q-switched Nd: YAG , uachtar hidroquinone, agus aigéad tranexamic béil, rud a d'eascair feabhas suntasach don chuid is mó d'othair.
      Riehl melanosis (RM), commonly called pigmented contact dermatitis, is considered an acquired form of allergic contact dermatitis, typically to fragrance and other ingredients of cosmetic products. Although it is considered as a dermatitis, it presents clinically with hyperpigmentation over the face and shows pigment incontinence with minimal eczematous changes on histology. The condition is more commonly seen in dark-skinned people, causing an important psychosocial impact. A recent study showing the higher effectiveness of mid-fluence QSNY 1064-nm laser in targetting the deep pigmentation of RM has also been conducted. Another study used a combination of therapies to include low-fluence, 1064-nm, Q-switched Nd: YAG laser, hydroquinone cream, and oral tranexamic acid, with the majority of patients experiencing significant improvement.
       Research Advances in the Treatment of Riehl’s Melanosis 37168093 
      NIH
      Is cineál riocht craiceann é Riehl's melanosis de bharr teagmháil le hailléirginí áirithe agus nochtadh do sholas na gréine. Tá sé mar thoradh ar lí tapa, forásach liath-donn ar an gcraiceann, rud a chuireann isteach go mór ar othair go meabhrach agus go fisiceach. Cé nach fios fós an chúis bheacht le Riehl's melanosis , léiríonn taighde atá ann cheana féin nasc láidir le nochtadh ailléirginí. Maidir leis an gcóireáil, baineadh triail as cógais thraidisiúnta agus teiripe léasair araon, go minic in éineacht le húsáid gníomhairí tuaradh a chuirtear i bhfeidhm ar an gcraiceann. Léirigh teiripe léasair, go háirithe ag baint úsáide as léasair Q-switched Nd:YAG , torthaí geallta maidir le cóireáil Riehl's melanosis. Tá torthaí dearfacha mar thoradh ar chur chuige cóireála éagsúla a chomhcheangal.
      Riehl's melanosis (RM) is a contact photodermatitis, with fast progressive gray-brown skin pigmentation as the main manifestation, which can seriously affect the psychology and physiology of patients. Currently, although the etiological factors of Riehl's melanosis is still be unknown, the existing literature proves clearly the cause of it is related to the contacting with suspected allergens. For decades, there has been no standard method for the treatment of RM, but with both conventional drug therapy and laser therapy having been attempted. Topical application of bleaching agents is mainly used as an auxiliary treatment modality. The laser treatment modality remains a hot spot, among which Q-switched Nd:YAG laser is well received for RM. Positive outcomes have been achieved by the combined treatment modalities attempted in recent years also achieve positive outcomes.